Serum tumor necrosis factor alpha receptors p55/p75 ratio and ovarian cancer detection

Rzymski, Paweł; Opala, Tomasz; Wilczak, Maciej; Woźniak, Jakub; Sajdak, Stefan

doi:10.1016/j.ijgo.2004.12.015

Cited by 15 publications

(9 citation statements)

References 25 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…(20,21) Expression of TNF-α and its receptors has been reported in esophageal, (22) prostatic, (23) follicular thyroid, (24) skin (25) and ovarian (26) cancers. TNF-α has also been described as an important promoter of cancer in different breast cancer cell lines, such as and MCF10A.…”

mentioning

confidence: 99%

“…(17) Several reports have stated that overexpression of p21 in breast carcinoma has been associated with accumulation of mtp53, (18,19) considered to be an indicator of poor prognosis. (20,21) Expression of TNF-α and its receptors has been reported in esophageal, (22) prostatic, (23) follicular thyroid, (24) skin (25) and ovarian (26) cancers. TNF-α has also been described as an important promoter of cancer in different breast cancer cell lines, such as MCF-7 (27) and MCF10A.…”

mentioning

confidence: 99%

See 1 more Smart Citation

Role of tumor necrosis factor‐α and its receptors in human benign breast lesions and tumors (in situ and infiltrative)

et al. 2006

View full text Add to dashboard Cite

The aim of the present study was to characterize the expression pattern of tumor necrosis factor (TNF)-α α α α and its receptors in breast samples (benign diseases, in situ carcinomas and infiltrating carcinomas), and to compare these results with those obtained previously for interleukin-6, p53 and p21 using the same samples in order to elucidate the effects of these cytokines on the proliferationapoptosis equilibrium. Immunoexpression of TNF-α α α α and its receptors (TNFRI and TNFRII) were studied by western blotting and immunohistochemistry. The percentage of samples positive for TNF-α α α α and TNFRII was higher in in situ carcinoma than in benign breast diseases, and TNFRII was even higher in infiltrating tumors. The percentage of samples positive for TNFRI was similar in the three groups. For the three proteins and in the three patient groups, immunoreactions were observed in the peripheral cytoplasm. In the positive samples, immunostaining for TNF-α α α α was more intense in infiltrating tumors than in the other two patient groups, whereas immunostaining for both receptors was higher in in situ carcinoma than in benign breast diseases, and even higher in infiltrating tumors. Comparing the TNF-α α α α results with previous results for mtp53, p21 and interleukin-6, we found an association between the expression of these four proteins and increasing malignancy. TNF-α α α α might be an important factor in breast cancer promotion as its proliferation and survival effects seems to be enhanced through the increased expression of TNFRII. Also, the pro-apoptotic pathway of TNFRI could be inhibited by p21 (which appeared increased in breast cancer), altering TNFRI effects in promoting the expression of several factors, such interleukin-6, which contribute to tumor promotion. (Cancer Sci 2006; 97: 1044-1049) T umor necrosis factor (TNF)-α seems to exert a key role in promoting many tumors to breast cancer. TNF-α is a 17-kDa polypeptide that was first described as a serum-derived substance that causes tumor cell death, (1) and is involved in skin carcinogenesis and the spread of a variety of carcinomas and sarcomas. It can induce tumor necrosis by affecting tumor vascularization and initiating apoptotic cell death, but paradoxically, it also can promote cell proliferation.(2,3) The action of TNF-α is mediated by two distinct receptors, named TNFRI (55 kDa) and TNFRII (75 kDa), both of which show a similar affinity for TNF-α in humans.(4-6) TNFRI is the major mediator of most TNF-α activities, (7) including apoptosis. (8,9) However, cell proliferation through Nuclear Factor kappa B(NF-κB) transcription factor activation (10,11) has also been reported in fibroblasts.(12) TNFRII has been described to mediate proliferation in some cells by acting as a thymocyte. (13) Another cytokine related to TNF-α and cell proliferation is interleukin (IL)-6. Recent studies have reported that high expression of IL-6 is associated with proliferation markers in breast cancer.(14) Both TNF-α and IL-6 could also be related to different f...

show abstract

mentioning

confidence: 99%

mentioning

confidence: 99%

Role of tumor necrosis factor‐α and its receptors in human benign breast lesions and tumors (in situ and infiltrative)

et al. 2006

View full text Add to dashboard Cite

show abstract

“…Higher expressions of TNF- α have been reported in various tumour tissues [ 22 , 24 , 28 , 35 , 36 ]. TNF- α expression and its action have also been reported in esophageal cancer [ 37 ], ovarian cancer [ 38 , 39 ], breast cancer [ 40 ], and follicular thyroid cancer as well [ 41 ]. The present study also found a significant inverse correlation between the circulating levels and tumoural protein expression of TNF- α .…”

Section: Discussionmentioning

confidence: 99%

Significance of TNF-αand the Adhesion Molecules: L-Selectin and VCAM-1 in Papillary Thyroid Carcinoma

Kobawala

Trivedi

Gajjar

et al. 2016

Journal of Thyroid Research

View full text Add to dashboard Cite

Circulating levels of TNF-α and the adhesion molecules L-Selectin and VCAM-1 as well as their expression in the primary tumors of patients with benign thyroid diseases and papillary thyroid carcinoma (PTC) have been determined in this study. The serum levels of TNF-α, L-Selectin, and VCAM-1 were significantly higher in patients with both benign thyroid diseases and PTC as compared to the healthy individuals. However, the levels of only TNF-α and L-Selectin, and not VCAM-1, were significantly higher in patients with PTC in comparison to those observed in patients with benign thyroid diseases. Further the expression of TNF-α and L-Selectin was also significantly higher in the primary tumors of PTC patients, relative to the benign thyroid diseases. The expression of L-Selectin and VCAM-1 significantly correlated with aggressive tumor behavior. In PTC patients, the circulating TNF-α levels significantly positively correlated with the levels of L-Selectin, while TNF-α immunoreactivity was significantly associated with VCAM-1 expression. Serum TNF-α was found to be a significant prognosticator for OS in PTC patients. Overall the results signify that the interaction between TNF-α and the adhesion molecules may have a role in thyroid carcinogenesis and understanding this complexity may offer potential therapeutic targets for better management of thyroid cancer.

show abstract

“…In addition, the ovarian cancer cells had the capacity for spontaneous secretion of more sTNF-R1, but less receptor type 2 [24]. Additionally, serum TNF-R1 level correlated with morphological ultrasound score and CA125 [22]. The observations made in Burger's study [25] showed a relationship between levels of CA125, sTNF-R1 and sTNF-R2 and risk of progression of epithelial ovarian malignancies.…”

Section: Discussionmentioning

confidence: 99%

Higher serum levels of tumour necrosis factor and its soluble receptors are associated with ovarian tumours

Mielczarek‐Palacz

Kondera-Anasz²,

Sikora³

2012

aoms

View full text Add to dashboard Cite

IntroductionTumour necrosis factor (TNF) and its soluble receptors type 1 (sTNF-R1) and type 2 (sTNF-R2) have been suggested as key mediators between apoptosis and cancer cell progression. The aim was to examine concentrations of the parameters in the serum of women with ovarian tumour and in the fluid from ovarian cysts of women with serous cystadenoma.Material and methodsThe study included 125 women with ovarian tumours. As a control, sera were obtained from 70 healthy female volunteers. Concentrations of TNF, sTNF-R1 and sTNF-R2 were measured by enzyme-linked immunosorbent assay (ELISA).ResultsSignificant increases of TNF, sTNF-R1 and sTNF-R2 were found in the serum of women with ovarian tumour in comparison to the control (p < 0.0001). The highest levels of all studied parameters were observed in women with ovarian cancer. In the ovarian cyst fluid the concentrations of the evaluated parameters increased significantly as compared to the serum (p < 0.0001).ConclusionsOur data showed changes in regulatory mechanisms of apoptosis in women with ovarian tumours which are associated with increased concentrations of all studied factors. Serum estimated TNF and especially sTNF-R may be used as complementary diagnostic markers in patients with ovarian tumours.

show abstract

Serum tumor necrosis factor alpha receptors p55/p75 ratio and ovarian cancer detection

Abstract: Serum TNF alpha p55/p75 ratio showed promising value in ovarian cancer detection.

Cited by 15 publications

References 25 publications

Role of tumor necrosis factor‐α and its receptors in human benign breast lesions and tumors (in situ and infiltrative)

Role of tumor necrosis factor‐α and its receptors in human benign breast lesions and tumors (in situ and infiltrative)

Significance of TNF-αand the Adhesion Molecules: L-Selectin and VCAM-1 in Papillary Thyroid Carcinoma

Higher serum levels of tumour necrosis factor and its soluble receptors are associated with ovarian tumours

Contact Info

Product

Resources

About